Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Platinum Global Fund (Long Only). This analysis is provided for institutional research purposes only and is not investment advice.
"Fund outperformed during Q1 market volatility through overweight Europe and China positions. New manager Ted Alexander is capitalizing on 'risk contango' by rotating into quality pharmaceutical stocks like AbbVie and Novartis, which offer better risk-adjusted returns than crowded technology names."
The Platinum Global Fund delivered -0.8% in Q1 2025, outperforming the benchmark which fell -2.0%. Ted Alexander became portfolio manager on March 3rd, inheriting a portfolio well-positioned for market volatility. The fund benefited from overweight positions in Europe, UK, and China, with Chinese stocks outperforming in February and early March. The strategy capitalizes on a 'risk contango' environment where years of crowding into risky technology businesses has created better opportunities in quality defensive stocks. The fund has rotated towards pharmaceutical manufacturers including AbbVie, AstraZeneca, Merck, and Novartis, viewing these as offering both downside protection and profit potential due to depressed valuations. US tariff uncertainty dominated markets, with Trump's regime announcement sending markets down 10% post-quarter. The portfolio maintains defensive positioning for potential US economic weakness while monitoring contagion effects in Europe and China. Higher cash levels from portfolio rotation will be reinvested by April's end.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction evident in clear strategic positioning around risk contango thesis, specific pharmaceutical stock selections, and geographic overweights. Manager articulates clear rationale for defensive rotation and maintains positions despite volatility.
Growth Outlook
Manager expresses cautious pessimism about market environment, citing tariff uncertainty, potential US economic weakness, and inflation shocks. However, sees opportunities in defensive positioning and geographic diversification.
Risk Appetite
Portfolio positioned defensively with rotation towards pharmaceuticals and consumer staples, higher cash levels, and focus on downside protection. Risk appetite is reduced but not extremely defensive.
Capital Deployment
Fund increased cash levels during portfolio rotation and took profits on strong performing positions. While planning to reinvest cash by April, current stance shows moderate de-risking and profit-taking activity.
Forward Guidance
Forward guidance indicates expectation of continued uncertainty, weaker US economy, and monitoring for contagion effects. Tone is cautious but not alarmist, with plans to complete portfolio rotation.
Language Signal
Language includes terms like 'uncertainty,' 'volatility,' 'shock,' and 'defensive positioning,' but balanced with opportunities in 'quality stocks' and 'profit potential.' Overall slightly negative but measured.
Perceived Risk
Manager identifies multiple significant risks including tariff uncertainty, potential economic weakness, inflation shocks, and contagion effects. Risk perception is elevated given market volatility and policy uncertainty.
Opportunity Density
Manager sees selective opportunities in pharmaceutical sector due to risk contango and geographic opportunities in Europe and China. Opportunity set is viewed as available but requires careful selection rather than broad deployment.
Time Horizon
Strategy focuses on medium-term positioning through market volatility with plans to complete portfolio rotation by April. Approach suggests measured patience rather than urgent short-term actions or very long-term positioning.
